
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is viewed favorably because its CGM platform is expanding from intensive diabetes care into the large T2NIT and OTC markets, where CONNECT showed a −1.6% A1c reduction vs. −0.7% for control, ~21% time-in-range improvement, and ~97% adherence over 26 weeks. The company’s Stelo/NutriSense experience suggests durable adoption will be driven by software, coaching, meal logging, and personalized insights, creating a differentiated engagement ecosystem that can support retention and utilization beyond sensor hardware alone. That growth story is reinforced by strong execution, with gross margin of 63.5%, adjusted EBITDA margin of 30.6%, cash and marketable securities of $2.42B, and a reiterated 2026 revenue outlook of $5.16B-$5.25B.
Bears say
DexCom is facing a negative fundamental outlook because its CGM experience still shows meaningful product limitations, including underutilized exercise and sleep functionality, weak engagement with Learn content, and compression lows that reduce overnight glucose-analysis reliability. The company also faces sector-level risks that could pressure growth and profitability, including regulatory delays, pricing pressure from payors and CMS, intense competition, and the high investment required to defend its market position. If CGM penetration fails to expand or competing products weaken its moat, the stock’s premium multiple would be harder to justify despite integration efforts with insulin pumps and broader distribution channels.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares